Form 4: Pfizer Executive Michael McDermott Reports Stock Transactions

Executive Vice President Michael McDermott reported the earn-out of stock appreciation rights and related tax and exercise price obligations resulting in changes to his beneficial ownership of Pfizer stock.

Summary

• On February 22, 2025, Michael McDermott, an Executive Vice President at Pfizer Inc., reported transactions involving Pfizer's common stock.
• These transactions included the earn-out of 11,125 stock appreciation rights at a price of $30.17.
• McDermott also had shares withheld to cover tax obligations (497 shares at $26.3) and the exercise price (9,925 shares at $26.08) related to the stock appreciation rights.
• Following these transactions, McDermott's direct ownership of Pfizer common stock decreased from 87,636 to 77,214 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about executive stock ownership.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the trading activities of company insiders. This filing indicates the exercise of stock appreciation rights, a common form of equity compensation.

Comparison to Industry Standards

• Stock appreciation rights are a common form of executive compensation, similar to stock options, used by many large corporations, including those in the pharmaceutical industry like Johnson & Johnson and Merck.
• The reporting requirements under Section 16(a) of the Securities Exchange Act are standard practice for corporate insiders in publicly traded companies globally.

Stakeholder Impact

• The filing provides transparency to shareholders regarding executive compensation and stock ownership.
• The transactions have a minor impact on the overall shareholding structure of the company.

Key Dates